References
- Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361(1), 11–21 (2009).
- Murtas C, Bruschi M, Candiano G et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. 7(9), 1394–1400 (2012).
- Hogan SL, Muller KE, Jennette JC, Falk RJ. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney Dis. 25(6), 862–875 (1995).
- Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 51(3), 901–907 (1997).
- Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 329(2), 85–89 (1993).
- Ponticelli C, Zucchelli P, Passerini P et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 48(5), 1600–1604 (1995).
- Jha V, Ganguli A, Saha TK et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 18(6), 1899–1904 (2007).
- Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2(8616), 869–872 (1988).
- du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am. J. Kidney Dis. 46(6), 1012–1029 (2005).
- Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney Dis. 44(3), 385–401 (2004).
- Cattran DC, Appel GB, Hebert LA et al.; North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59(4), 1484–1490 (2001).
- Praga M, Barrio V, Juárez GF, Luño J; Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71(9), 924–930 (2007).
- Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47(2), 233–240 (2006).
- Senthil Nayagam L, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol. Dial. Transplant. 23(6), 1926–1930 (2008).
- Chan TM, Lin AW, Tang SC et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology 12(6), 576–581 (2007).
- KDIGO. Clinical practice guidelines for glomerulonephritis. Kidney Int. Suppl. 2, 186–197 (2012).
- Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 23, 1416–1425 (2012).
- Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360(9337), 923–924 (2002).
- Fervenza FC, Abraham RS, Erickson SB et al.; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5(12), 2188–2198 (2010).
- Ruggenenti P, Cravedi P, Sghirlanzoni MC et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin. J. Am. Soc. Nephrol. 3(6), 1652–1659 (2008).
- Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 9(3), 444–450 (1998).
- Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment. Rheumatology 51(6), 1107–1111 (2012).